Navigation Links
Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
Date:10/23/2008

--Honor recognizes excellence in ChIP, DNA methylation innovation and service--

SAN DIEGO, Oct. 23 /PRNewswire/ -- Genpathway, Inc. announced today that the company has received the 2008 Frost & Sullivan North American Services in Drug Discovery Technologies Healthcare Innovation Award.

The award recognizes Genpathway for providing superior services for chromatin immunoprecipitation (ChIP) and DNA methylation assays that directly contribute to discoveries in gene regulation, epigenetics, and gene transcription.

"Frost & Sullivan recognizes Genpathway for its outstanding efforts to provide researchers an efficient and economical solution to fast-track notoriously difficult ChIP procedures," explained Frost & Sullivan industry analyst Christianne Bird. "As the recognized experts in ChIP, Genpathway consistently is the first to deliver cutting-edge technologies to the market and teams with top technology providers to offer the newest ChIP techniques available. For its commitment to providing innovative services to advance life sciences research and drug discovery and its position as the leader in its field, Frost & Sullivan is pleased to present Genpathway the 2008 North America Services in Drug Discovery Technologies Healthcare Innovation Award."

"Genpathway is honored to be recognized with this prestigious award from Frost & Sullivan," said Mary Harper, PhD, Chief Scientific Officer of Genpathway. "As interest in and demand for ChIP and DNA methylation assays continues to expand rapidly, our goal is to provide researchers across a broad range of disease areas and research fields a fast-track to discovery using our whole-genome assays. Genpathway's complete ChIP and DNA IP solutions are proving highly valuable for understanding gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications."

Frost & Sullivan presents its Annual Award for Innovation in Healthcare to the company that has introduced truly innovative products, practices, or ideas within its industry. The award recognizes the company's innovative contributions that make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality of life for patients; or that lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services. The selection of this award is based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

About Genpathway (http://www.genpathway.com)

Genpathway is a pharmacogenomics company that provides specialized drug discovery, research, and development services and develops novel diagnostic biomarkers that predict drug responses, enabling personalized treatments. The company applies its proprietary chromatin and methylated DNA immunoprecipitation (ChIP) technology to understand gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications. Based on the information gained from its technology, Genpathway is developing and commercializing a broad portfolio of clinically validated molecular diagnostic products and services that will enable the accurate selection of specific drugs to efficaciously treat individuals with cancer, immune disorders, and other serious diseases.

About Frost & Sullivan (http://www.frost.com)

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

Contact:

Mary Moynihan

M2Friend Biocommunications

(802) 951-9600

mary@m2friend.com


'/>"/>
SOURCE Genpathway
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
2. Frost & Sullivan Acknowledges ISTO Technologies Role in Developing Advanced Biologic Products for Bone Healing
3. Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy
4. Celsis Receives Frost & Sullivan 2008 Best Practices Award
5. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
6. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
7. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
8. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
9. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
10. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
11. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):